Price to Sales (P/S)
since 2005
Paying user area
Try for free
Celgene Corp. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Celgene Corp., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Net product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Celgene Corp. Annual Report.
- Share Price Trends
- The share price demonstrated an overall upward trajectory from 2006 to 2019, beginning at $20.5 in March 2006 and peaking at $123.43 in February 2015. Subsequent years showed some volatility and a downward correction, declining to $89.71 by February 2019. This suggests significant growth in investor valuation during the early period, followed by a moderate reduction in value more recently.
- Sales Per Share Trends
- Sales per share exhibited consistent growth throughout the period. Starting at $0.65 in 2006, sales per share increased steadily, reaching $21.74 in 2019. This indicates strong, sustained revenue growth on a per-share basis over the thirteen-year span.
- Price-to-Sales (P/S) Ratio Trends
- The P/S ratio showed a declining trend over the observed years. Beginning at a high of 31.74 in 2006, the ratio decreased markedly to 4.13 by 2019. This decline indicates that the share price growth was progressively outpaced by increases in sales per share, resulting in the stock becoming less expensive relative to sales.
- Overall Analysis
- The data reflects a company with robust revenue growth, as illustrated by the strong upward trend in sales per share. Although the share price generally increased over time, the more rapid increase in sales led to a significant reduction in the price-to-sales ratio. This trend suggests an improving valuation in terms of sales fundamentals, potentially indicating that the stock became more attractively valued relative to its revenue generation capacity at the end of the period. The volatility in share price, especially post-2015, may reflect market corrections or changing investor sentiment after substantial prior gains.
Comparison to Competitors
Celgene Corp., P/S, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | |||||||||||||
| Feb 7, 2018 | |||||||||||||
| Feb 10, 2017 | |||||||||||||
| Feb 11, 2016 | |||||||||||||
| Feb 20, 2015 | |||||||||||||
| Feb 13, 2014 | |||||||||||||
| Feb 15, 2013 | |||||||||||||
| Feb 22, 2012 | |||||||||||||
| Mar 1, 2011 | |||||||||||||
| Feb 18, 2010 | |||||||||||||
| Feb 17, 2009 | |||||||||||||
| Feb 20, 2008 | |||||||||||||
| Feb 27, 2007 | |||||||||||||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 26, 2019 | ||
| Feb 7, 2018 | ||
| Feb 10, 2017 | ||
| Feb 11, 2016 | ||
| Feb 20, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 22, 2012 | ||
| Mar 1, 2011 | ||
| Feb 18, 2010 | ||
| Feb 17, 2009 | ||
| Feb 20, 2008 | ||
| Feb 27, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., P/S, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Feb 26, 2019 | ||
| Feb 7, 2018 | ||
| Feb 10, 2017 | ||
| Feb 11, 2016 | ||
| Feb 20, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 22, 2012 | ||
| Mar 1, 2011 | ||
| Feb 18, 2010 | ||
| Feb 17, 2009 | ||
| Feb 20, 2008 | ||
| Feb 27, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).